Nimacimab dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Nimacimab is an antibody that blocks the cannabinoid CB1 receptor outside the brain. On its own it did little. With semaglutide, people lost 22.3 percent of their weight at 52 weeks and regained about half as much during a break.
Evidence grade for Nimacimab: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 0 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Nimacimab is an antibody shot from Skye Bioscience. It blocks the CB1 receptor, the one cannabis acts on, but only outside the brain. The goal is weight loss without the mood problems of an older drug, rimonabant. It is not approved.
What people take it for
- More weight loss on top of semaglutide.
- Less weight regain after stopping a GLP-1 drug.
What studies in people showed
On its own, it missed its target. Added to semaglutide, people lost 13.2 percent of their weight at 26 weeks. Semaglutide alone took off 10.25 percent. At 52 weeks, people on both had lost 22.3 percent. During a 13-week break from the drugs, they regained about half as much as expected. The later results came from a company release about a small study.
What people report
Reports, not study results
The good
- In the studies on this page, people who stopped both drugs for 13 weeks regained about half as much weight.
The bad
- On its own, it did not work in the study on this page.
- The studies on this page do not list side effects, and we have not collected user reports on this one yet.
Where these come from: All of it is from the study record and company release on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Weight coming back after you stop is the real problem with these drugs. This is one small study. The regain fix that works today is muscle, so lift.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Nimacimab?
Nimacimab is an antibody that blocks the cannabinoid CB1 receptor outside the brain. On its own it did little. With semaglutide, people lost 22.3 percent of their weight at 52 weeks and regained about half as much during a break.
Nimacimab, from Skye Bioscience, is an antibody that blocks the CB1 receptor, the one cannabis acts on. It cannot get into the brain. The goal is to get the body benefits of blocking CB1 without the mood problems that sank an older drug, rimonabant. In the mid-stage CBeyond study, nimacimab alone missed its target. But nimacimab plus semaglutide took off 13.2 percent of weight at 26 weeks, against 10.25 percent on semaglutide alone. In the follow-on part, people on both drugs had lost 22.3 percent at 52 weeks. During a 13-week break from the drugs, they regained about half as much weight. A higher-dose study started in 2026.
How does Nimacimab work?
It turns down CB1 receptors in fat, liver and gut. That cuts fat building and helps the body use insulin better, without reaching the brain.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- 144,983 Da (monoclonal antibody)
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Nimacimab, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025CBeyond: nimacimab alone and with semaglutide in obesity
Added to semaglutide, the antibody beat semaglutide alone by a small margin. After half a year people on both drugs had lost about 13% of body weight, against about 10% for semaglutide by itself. On its own, nimacimab missed its target. So it looks like an add-on rather than a treatment in its own right. This was a small early trial, and a three point gap in one small study can vanish in a larger one.
Combination 13.2% versus 10.25% on semaglutide alone at 26 weeks.
- Study in people2026Skye reports positive CBeyond extension results
The pairing kept working through a full year, and it slowed the weight coming back. People on both drugs were about 22% lighter at 52 weeks. When treatment stopped for 13 weeks, they regained about half as much as expected. Regain after stopping is the unsolved problem with these drugs, so that second figure is the interesting one. It comes from a company announcement about a small extension study, not from a published paper.
22.3% loss at 52 weeks; 50% less regain during a 13-week drug holiday.
Common questions
Has Nimacimab been tested in people?
Yes. 0 people given it across 2 completed trials cited here, 0 of which found nothing. Nimacimab is an antibody that blocks the cannabinoid CB1 receptor outside the brain. On its own it did little. With semaglutide, people lost 22.3 percent of their weight at 52 weeks and regained about half as much during a break.
What is the Nimacimab dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 0 people given it
Is Nimacimab FDA-approved?
Investigational; in mid-stage studies
Is this related to rimonabant?
Same target, different approach. Rimonabant got into the brain and caused depression and anxiety. Nimacimab is an antibody that stays out of the brain, and the mid-stage study did not show those mood problems.